Orange Book product · Generic (ANDA)
ORPHENADRINE CITRATE
ORPHENADRINE CITRATE
At a glance
May 24, 2006
Approved
Generic (ANDA)
Application
AP
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
May 24, 2006
20 yr 4 mo ago
Today
Pharmaceutical detail
Active ingredient
ORPHENADRINE CITRATE
Strength
30MG/ML
Dosage form
INJECTABLE
Route
INJECTION
TE code
AP
Application
ANDA 040484
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
Yes
Active-ingredient family
View full familyGeneric (ANDA) of ORPHENADRINE CITRATE
- —NORFLEXBrand (NDA)
NDA 013055 · PAI HOLDINGS PHARM
- —NORFLEXBrand (NDA)
NDA 012157 · BAUSCH
- 2012ORPHENADRINE CITRATEGeneric (ANDA)
ANDA 091158 · UNICHEM
- 2011ORPHENADRINE CITRATEGeneric (ANDA)
ANDA 090585 · SAGENT PHARMS
- 2003ORPHENADRINE CITRATEGeneric (ANDA)
ANDA 040463 · HIKMA
- 2000ORPHENADRINE CITRATEGeneric (ANDA)
ANDA 040368 · STEVENS J
- 2000ORPHENADRINE CITRATEGeneric (ANDA)
ANDA 040327 · SANDOZ
- 1999ORPHENADRINE CITRATEGeneric (ANDA)
ANDA 040249 · RISING
- 1998ORPHENADRINE CITRATEGeneric (ANDA)
ANDA 040284 · LUPIN
- 1983ORPHENADRINE CITRATEGeneric (ANDA)
ANDA 088067 · ASCOT
- 1982ORPHENADRINE CITRATEGeneric (ANDA)
ANDA 084779 · WATSON LABS
- —ORPHENADRINE CITRATEGeneric (ANDA)
ANDA 087062 · WATSON LABS
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
